The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics

• Published in: Journal of cardiovascular pharmacology Vol. 12 Suppl 4; p. S129
• Main Authors: Lettieri, J T, Krol, G J, Yeh, S C, Burkholder, D E, Zinny, M, O'Donnell, D
• Format: Journal Article
• Language: English
• Published: United States 1988
• Subjects: Adult; African Continental Ancestry Group; Aged; Aging - physiology; Blood Pressure - drug effects; Continental Population Groups; European Continental Ancestry Group; Humans; Hypertension - drug therapy; Hypertension - physiopathology; Male; Middle Aged; Nitrendipine - pharmacokinetics; Nitrendipine - pharmacology; Nitrendipine - therapeutic use; Time Factors
• ISSN: 0160-2446
• DOI: 10.1097/00005344-198806124-00028

The pharmacokinetics and pharmacodynamics of a single 20-mg dose of nitrendipine (NTP) were studied in four groups of subjects (n = 9 per group). Group 1 were young white normotensive males, Group 2 were elderly white hypertensive males, Group 3 were black hypertensive males aged 40-55 years, and Group 4 were white hypertensive males aged 40-55 years. All other medications were withdrawn prior to NTP dosing. NTP was given in the morning 1 h after breakfast. Plasma samples for NTP assay were collected at predetermined times up to 48 h after dosing. Blood pressure was monitored before dosing, and at 0.5, 1, 3, 5, 12, and 24 h postdose. Pharmacokinetic parameters were found to be dependent on age. The area under the curve for Groups 1, 2, 3, and 4 was 50.5 +/- 19.4, 186 +/- 120, 107 +/- 49, and 88 +/- 43 ng h/ml, respectively (p less than 0.05). Corresponding values of elimination half-life were 9.9 +/- 1.3, 20 +/- 6.5, 13.3 +/- 6.1, and 15.9 +/- 8.0 h (p less than 0.05). Both diastolic and systolic blood pressures were significantly reduced from the baseline value in Groups 2, 3, and 4, with diastolic pressure remaining significantly lower than baseline at 24 h postdose. Based on the increased plasma levels and slower elimination of NTP in the elderly, as well as the measured blood pressure lowering, once daily dosing of NTP may be appropriate in some patients.